The U.S. Judicial Panel on Multidistrict Litigation has approved new MDLs regarding cholesterol drug Lipitor and vaginal mesh made by Neomedic to treat pelvic prolapse and incontinence in women.
Drug maker Pfizer had opposed the consolidation of 56 Lipitor cases into an MDL, partly on the grounds that the formation of a MDL would prompt an “avalanche of filings” of nonviable cases in an effort to coerce a settlement out of the pharmaceutical company. But the drug maker was most amenable to centralization in the District of South Carolina. Plaintiffs differed on which district they favored for centralization.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
